arrow
M

Mustapha Tehfé

université de montréal
H指数:23
被引数:7,895

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2025

2025年加拿大东部消化道肿瘤共识会议

2026-04-180
OAAI
Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial

粪便菌群移植联合免疫治疗非小细胞肺癌和黑色素瘤: fmt-luminate 2期临床试验

2026-01-280
OAAI
Neoadjuvant chemo-immunotherapy in Non-Small Cell Lung Cancer: Can Positron Emission Tomography scan predict complete pathological response?

非小细胞肺癌的新辅助化疗免疫治疗:正电子发射断层扫描能否预测完全病理缓解?

2025-10-280
PRE
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC
2024-12-011
OA
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E

Pembrolizumab联合Binimetinib联合化疗或不联合化疗治疗MSS/pMMR转移性结直肠癌: 来自651主题的队列A、C和E的结果

2024-06-010
PRE
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/ gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4year (y) follow-up (FU) of CheckMate 649
2024-06-010
PRE
Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D

Pembrolizumab联合mFOLFOX7或FOLFIRI治疗微卫星稳定/错配修复熟练的转移性结直肠癌: 主题演讲-651队列B和D

2024-06-014
PRE
Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma
2023-03-1615
PRE
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus

CheckMate 649研究的简明语言摘要: nivolumab联合化疗与单独化疗治疗未经治疗的晚期或转移性胃癌或食道癌的比较

2023-03-151
OA
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

CCTG PA.7吉西他滨和nab-紫杉醇联合或不联合durvalumab和tremelimumab作为转移性胰腺导管腺癌初始治疗的II期试验

2022-08-2657
OAAI
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

一线nivolumab联合化疗与单纯化疗治疗晚期胃癌,胃食管交界处和食管腺癌 (CheckMate 649): 一项随机,开放标签,3期试验

LANCET
IF88.5
2021-07-011.7K
OAAI
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study
2021-01-0158
PREAI